The lead product Mytesi (crofelemer) is an oral plant-based prescription drug made from sustainable sources and is FDA-approved for treatment of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and generates revenue. The company is expanding crofelemer across multiple indications including cancer-related diarrhea, rare diseases, and animal health applications while maintaining a focus on plant-based, non-opioid therapeutic solutions.
Cyborg Score Rationale
Jaguar faces headwinds as a commercial-stage biotech with a market cap of only ~$3.7M and declining stock price momentum (currently $0.85 vs. 52-week high of $15.75). However, the company has FDA-approved revenue-generating product (Mytesi) and multiple Phase II/III programs with recent positive data on crofelemer. Clinical validation and market expansion efforts provide upside, but capital constraints and execution risk remain significant concerns.
Top Insights
FDA-approved Mytesi generates revenue for HIV/AIDS-related diarrhea; company pursuing label expansion across cancer, rare diseases, and IBS indications
Recently submitted amended protocol to FDA for potential expedited approval pathway for crofelemer in microvillus inclusion disease (MVID)
Canalevia-CA1 received FDA conditional approval for chemotherapy-induced diarrhea in dogs; pursuing EMA approval for broader canine diarrhea indication
Market capitalization has collapsed 76% from 52-week high ($15.75 to $0.85), indicating severe investor skepticism or technical distress
Named Competitors
Anti-secretory antidiarrheal agents — Traditional non-prescription and prescription antidiarrheals
GI disorder therapeutics — Prescription treatments for IBS, diarrhea, and related conditions
Recent Developments
(January 2026) Jaguar Animal Health granted U.S. rights to crofelemer drugs and entered license agreement with Future Pak
(December 2025) FDA awarded $240,000 grant in support of Canalevia-CA1; company presented promising crofelemer trial results
(November 2025) Jaguar Animal Health secured $10.8M note agreement; company secured patent for crofelemer in short bowel syndrome
(November 2025) Jaguar Health reported Q3 2025 revenue up ~4% versus Q2 2025
Open the full interactive Jaguar Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.